Myelofibrosis is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, ineffective hematopoiesis, splenomegaly, and constitutional symptoms. It can arise de novo or evolve from other myeloproliferative disorders.
Novartis introduced new long-term social impact and sustainability targets covering access, global health, emissions, waste and water. The plan includes a 2030 access goal and net-zero across the value chain by 2040.
Ruxolitinib remains the standard frontline therapy for intermediate-2 and high-risk myelofibrosis, with phase 3 and real-world data showing spleen and symptom benefits. Cytopenias, transfusion needs and resistance after 2 to 3 years continue to drive interest in new combinations.
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
Incyte executives presented a post-Jakafi growth strategy at the Barclays conference, outlining four product launches and pipeline progress in hematology, immunology, and solid tumors ahead of Jakafi's loss of exclusivity in 2029.
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median overall survival of 27 months versus 11.2 months with standard treatment.
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median survival of 27 months versus 11.2 months with standard treatment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07750574 |
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07734077 |
Revumenib in Patients With Myelofibrosis |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07708272 |
QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07623161 |
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib |
RECRUITING | PHASE3 |
| NCT07608666 |
Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07551427 |
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis |
RECRUITING | PHASE2 |
| NCT07521046 |
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07498205 |
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts |
NOT_YET_RECRUITING | PHASE4 |
| NCT07480824 |
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects |
RECRUITING | PHASE1 |
| NCT07447817 |
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias |
NOT_YET_RECRUITING | PHASE2 |
